Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Active specific immunotherapy in malignant melanoma.

D L Morton1, L J Foshag, J A Nizze

  • 1Division of Surgical Oncology, John Wayne Cancer Clinic, Los Angeles, CA.

Seminars in Surgical Oncology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer.

Seminars in oncology·2001
Same author

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma.

CA: a cancer journal for clinicians·2001
Same author

Immunology of gangliosides.

Indian journal of experimental biology·2001
Same author

Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2000
Same journal

Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.

Seminars in surgical oncology·2003
Same journal

Preoperative chemoradiation for locally advanced rectal adenocarcinoma-the University of Florida experience.

Seminars in surgical oncology·2003
Same journal

Postoperative adjuvant therapy for pancreatic cancer.

Seminars in surgical oncology·2003
Same journal

Conformal chemoradiation for primary and metastatic liver malignancies.

Seminars in surgical oncology·2003
Same journal

Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.

Seminars in surgical oncology·2003
Same journal

Combined modality therapy in esophageal cancer: the Memorial experience.

Seminars in surgical oncology·2003
See all related articles

This study evaluated a new melanoma cell vaccine for high-risk patients. Combining it with cyclophosphamide did not improve immune response or clinical outcomes, suggesting a need for better immunomodulators.

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • High-risk and recurrent melanoma present significant treatment challenges.
  • Active specific immunotherapy aims to stimulate an immune response against cancer.
  • Suppressor cells can impede effective anti-tumor immunity.

Purpose of the Study:

  • To evaluate a new polyvalent melanoma cell vaccine in patients with high-risk or recurrent melanoma.
  • To assess the role of low-dose cyclophosphamide as an immunomodulator in conjunction with the vaccine.
  • To explore strategies for enhancing immune responses and improving melanoma patient prognosis.

Main Methods:

  • Clinical trials involving active specific immunotherapy with a polyvalent melanoma cell vaccine.
  • Administration of the vaccine alone and in combination with low-dose cyclophosphamide.

Related Experiment Videos

  • Monitoring of suppressor cell activity, humoral immune response to melanoma-associated antigens, and clinical course.

    • Main Results:

    • Low-dose cyclophosphamide reduced suppressor cell activity in some patients.
    • The addition of cyclophosphamide did not enhance humoral immune responses to melanoma antigens.
    • Clinical outcomes were not favorably influenced by the addition of cyclophosphamide.

    Conclusions:

    • While cyclophosphamide can modulate suppressor cells, it did not improve immune responses or clinical prognosis in this melanoma immunotherapy trial.
    • Further research into alternative or combination immunomodulators is warranted, especially for patients with persistent high suppressor cell activity.
    • Optimizing the melanoma vaccine and employing effective immunomodulators hold promise for improving patient prognosis by enhancing anti-tumor immunity.